PRAME gene expression in childhood acute lymphoblastic leukemia

Cancer Genetics and Cytogenetics

Volumn 138, Issue 1, 2002, Pages 89-91

  Steinbach, Daniel ^a   Viehmann, Susanne ^b   Zintl, Felix ^a   Gruhn, Bernd ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; FEMALE; GENE OVEREXPRESSION; HUMAN; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE;

ANTIGENS, NEOPLASM; CHILD; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0036804801     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(02)00582-4     Document Type: Article

References (12)

1. Schrappe M., Reiter A., Zimmermann M., Harbott J., Ludwig W.D., Henze G., Gadner H., Odenwald E., Riehm H. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Leukemia. 14:2000;2205-2222.
2. Schrappe M., Reiter A., Harbott J., Zimmermann M., Henze G., Boos J., Gadner H., Ludwig W.D., Riehm H. Improved risk-adapted treatment of childhood ALL with a new stratification system based on early response, genetics, age, and WBC. first interim analysis of trial ALL-BFM 95 Blood. 98:2001;2999.
3. Ikeda H., Lethe B., Lehmann F., van Baren N., Baurain J.F., de Smet C., Chambost H., Vitale M., Moretta A., Boon T., Coulie P.G. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 6:1997;199-208.
4. van Baren N., Chambost H., Ferrant A., Michaux L., Ikeda H., Millard I., Olive D., Boon T., Coulie P.G. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol. 102:1998;1376-1379.
5. Greiner J., Ringhoffer M., Simikopinko O., Szmaragowska A., Huebsch S., Maurer U., Bergmann L., Schmitt M. Simultaneous expression of different immunogenic antigens in acute myeloid leukemia. Exp Hematol. 28:2000;1413-1422.
6. Kessler J.H., Beekman N.J., Bres-Vloemans S.A., Verdijk P., van Veelen P.A., Kloosterman-Joosten A.M., Vissers D.C., ten Bosch G.J., Kester M.G., Sijts A., Wouter Drijhout J., Ossendorp F., Offringa R., Melief C.J. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med. 193:2001;73-88.
7. Thurner B., Haendle I., Roder C., Dieckmann D., Keikavoussi P., Jonuleit H., Bender A., Maczek C., Schreiner D., von den Driesch P., Brocker E.B., Steinman R.M., Enk A., Kampgen E., Schuler G. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 190:1999;1669-1678.
8. Marchand M., van Baren N., Weynants P., Brichard V., Dreno B., Tessier M.H., Rankin E., Parmiani G., Arienti F., Humblet Y., Bourlond A., Vanwijck R., Lienard D., Beauduin M., Dietrich P.Y., Russo V., Kerger J., Masucci G., Jager E., De Greve J., Atzpodien J., Brasseur F., Coulie P.G., van der Bruggen P., Boon T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer. 80:1999;219-230.
9. Matsushita M., Ikeda H., Kizaki M., Okamoto S., Ogasawara M., Ikeda Y., Kawakami Y. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. Br J Haematol. 11:2001;916-926.
10. Steinbach D., Hermann J., Viehmann S., Zintl F., Gruhn B. Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogenet. 133:2002;118-123.
11. Raff T., van der Giet M., Endemann D., Wiederholt T., Paul M. Design and testing of β-actin primers for RT-PCR that do not co-amplify processed pseudogenes. BioTechniques. 23:1997;456-460.
12. Watari K., Tojo A., Nagamura-Inoue T., Nagamura F., Takeshita A., Fukushima T., Motoji T., Tani K., Asano S. Identification of a melanoma antigen, PRAME, as a BCR/ABL-inducible gene. FEBS Lett. 466:2000;367-371.